ING Group’s Pacific Biosciences PACB Stock Holding History

ING Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-117,806	Closed	-$637K	–	801
2018 Q3	$637K	Sell	117,806 -90,196	-43%	-$387K	0.01%	457
2018 Q2	$738K	Buy	208,002 +5	+0%	+$14	0.01%	385
2018 Q1	$426K	Hold	207,997	–	–	0.01%	513
2017 Q4	$549K	Buy	+207,997	New	+$728K	0.01%	478
2016 Q4	–	Sell	-43,500	Closed	-$384K	–	588
2016 Q3	$384K	Sell	43,500 -32,520	-43%	-$272K	﹤0.01%	462
2016 Q2	$535K	Sell	76,020 -70,980	-48%	-$648K	0.01%	329
2016 Q1	$1.25M	Sell	147,000 -62,374	-30%	-$613K	0.02%	269
2015 Q4	$2.75M	Sell	209,374 -40,626	-16%	-$364K	0.02%	381
2015 Q3	$913K	Hold	250,000	–	–	0.01%	449
2015 Q2	$1.44M	Hold	250,000	–	–	0.01%	474
2015 Q1	$1.46M	Hold	250,000	–	–	0.01%	548
2014 Q4	$1.96M	Buy	+250,000	New	+$1.6M	0.01%	490
2014 Q3	–	Sell	-250,000	Closed	-$1.54M	–	667
2014 Q2	$1.54M	Hold	250,000	–	–	0.01%	488
2014 Q1	$1.34M	Hold	250,000	–	–	0.01%	530
2013 Q4	$1.31M	Buy	+250,000	New	+$1.15M	0.01%	528

Other funds holding PACB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ING Group's PACB Position: Q4 2018 in Review

ING Group sold out of Pacific Biosciences (PACB) in Q4 2018, closing a stake of 117,806 shares — an estimated $637K sold.

ING Group first reported a position in PACB in Q4 2013 and held it in 15 quarters. The position peaked at $2.75M in Q4 2015. 155 funds tracked by Wall St. Rank hold PACB as of Q4 2018.

ING Group reported no remaining Pacific Biosciences position as of Q4 2018 after selling out during the quarter.
ING Group sold 117,806 Pacific Biosciences shares in Q4 2018, an estimated $637K.
ING Group first reported a position in Pacific Biosciences in Q4 2013 and held it in 15 quarters.
ING Group's Pacific Biosciences position peaked at $2.75M in Q4 2015.
155 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2018.

Based on ING Group's 13F filing for Q4 2018, filed 13 Feb 2019.